Nothing Special   »   [go: up one dir, main page]

WO2000023058A3 - Use of an antianaerobic-bacterial or/and antiprotozoal agent (preferably metronidazole) in the manufacture of a medicament for the treatment of haemorrhoids - Google Patents

Use of an antianaerobic-bacterial or/and antiprotozoal agent (preferably metronidazole) in the manufacture of a medicament for the treatment of haemorrhoids Download PDF

Info

Publication number
WO2000023058A3
WO2000023058A3 PCT/GB1999/003449 GB9903449W WO0023058A3 WO 2000023058 A3 WO2000023058 A3 WO 2000023058A3 GB 9903449 W GB9903449 W GB 9903449W WO 0023058 A3 WO0023058 A3 WO 0023058A3
Authority
WO
WIPO (PCT)
Prior art keywords
haemorrhoids
bacterial
antianaerobic
medicament
manufacture
Prior art date
Application number
PCT/GB1999/003449
Other languages
French (fr)
Other versions
WO2000023058A2 (en
Inventor
Kartar Tirath Lalvani
Original Assignee
Vitabiotics Limited
Kartar Tirath Lalvani
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vitabiotics Limited, Kartar Tirath Lalvani filed Critical Vitabiotics Limited
Publication of WO2000023058A2 publication Critical patent/WO2000023058A2/en
Publication of WO2000023058A3 publication Critical patent/WO2000023058A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A method of treating a patient suffering from haemorrhoids, which method comprises administering to the patient at least one anti-anaerobic-bacterial and/or anti-protozoal agent e.g. metronidazole effective against micro-organisms present in the gut.
PCT/GB1999/003449 1998-10-16 1999-10-18 Use of an antianaerobic-bacterial or/and antiprotozoal agent (preferably metronidazole) in the manufacture of a medicament for the treatment of haemorrhoids WO2000023058A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9822681.4 1998-10-16
GBGB9822681.4A GB9822681D0 (en) 1998-10-16 1998-10-16 Method of treatment

Publications (2)

Publication Number Publication Date
WO2000023058A2 WO2000023058A2 (en) 2000-04-27
WO2000023058A3 true WO2000023058A3 (en) 2000-07-06

Family

ID=10840749

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1999/003449 WO2000023058A2 (en) 1998-10-16 1999-10-18 Use of an antianaerobic-bacterial or/and antiprotozoal agent (preferably metronidazole) in the manufacture of a medicament for the treatment of haemorrhoids

Country Status (2)

Country Link
GB (1) GB9822681D0 (en)
WO (1) WO2000023058A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005058345A1 (en) 2005-12-06 2007-06-14 Kern, Andreas, Dr. med. Use of an oral antibiotic

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RO89526A2 (en) * 1984-02-20 1986-05-30 Intreprinderea De Antibiotice,Ro PROCESS FOR OBTAINING A DRUG-ADMINISTRATIVE MEDICAMENTEU0 PRODUCT IN INFECTIONS WITH ANAEROBIC GERMS
JPH0491036A (en) * 1990-08-06 1992-03-24 Tatsuya Hashioka External preparation for anus
EP0579435A1 (en) * 1992-07-14 1994-01-19 CYCLOPS h.f. Cyclodextrin complexation
WO1994012164A1 (en) * 1992-11-26 1994-06-09 The Wellcome Foundation Limited Combination of atovaquone with proguanil for the treatment of protozoal infections
US5354866A (en) * 1989-05-23 1994-10-11 Abbott Laboratories Retroviral protease inhibiting compounds
CN1097306A (en) * 1993-07-12 1995-01-18 中国医科大学第二临床学院 Compound anti-inflammation suppository
WO1996003135A1 (en) * 1994-07-25 1996-02-08 Milankovits Marton Pharmaceutical compositions, mainly vaginal suppository, containing many different active ingredients
WO1998043644A1 (en) * 1997-03-31 1998-10-08 David Granstrom Formulations and methods to treat and prevent equine protozoal myeloencephalitis

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RO89526A2 (en) * 1984-02-20 1986-05-30 Intreprinderea De Antibiotice,Ro PROCESS FOR OBTAINING A DRUG-ADMINISTRATIVE MEDICAMENTEU0 PRODUCT IN INFECTIONS WITH ANAEROBIC GERMS
US5354866A (en) * 1989-05-23 1994-10-11 Abbott Laboratories Retroviral protease inhibiting compounds
JPH0491036A (en) * 1990-08-06 1992-03-24 Tatsuya Hashioka External preparation for anus
EP0579435A1 (en) * 1992-07-14 1994-01-19 CYCLOPS h.f. Cyclodextrin complexation
WO1994012164A1 (en) * 1992-11-26 1994-06-09 The Wellcome Foundation Limited Combination of atovaquone with proguanil for the treatment of protozoal infections
CN1097306A (en) * 1993-07-12 1995-01-18 中国医科大学第二临床学院 Compound anti-inflammation suppository
WO1996003135A1 (en) * 1994-07-25 1996-02-08 Milankovits Marton Pharmaceutical compositions, mainly vaginal suppository, containing many different active ingredients
WO1998043644A1 (en) * 1997-03-31 1998-10-08 David Granstrom Formulations and methods to treat and prevent equine protozoal myeloencephalitis

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BISWAS P: "Metronidazole in haemorrhoids", J INDIAN MED ASSOC, OCT 1 1968, 51 (7) P344-6, INDIA, XP000885886 *
BROOK I. ET AL: "Aerobic and anaerobic microbiology of infected hemorrhoids", AMERICAN JOURNAL OF GASTROENTEROLOGY, 91/2 (333-335), United States, XP000885600 *
CARAPETI EA ET AL: "Double-blind randomised controlled trial of effect of metronidazole on pain after day-case haemorrhoidectomy", LANCET, JAN 17 1998, 351 (9097) P169-72, ENGLAND, XP000885602 *
DATABASE WPI Section Ch Week 198701, Derwent World Patents Index; Class B03, AN 1987-005119, XP002135643 *
DATABASE WPI Section Ch Week 199219, Derwent World Patents Index; Class B05, AN 1992-147958, XP002135646 *
DATABASE WPI Section Ch Week 199719, Derwent World Patents Index; Class B03, AN 1997-204067, XP002135644 *

Also Published As

Publication number Publication date
GB9822681D0 (en) 1998-12-09
WO2000023058A2 (en) 2000-04-27

Similar Documents

Publication Publication Date Title
WO2002056912A3 (en) Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent
WO2002041837A3 (en) Treatment of mucositis
UA32429C2 (en) Agent for treatment of patient with enuresis
IL156122A0 (en) Geldanamycin derivative and method of treating cancer using same
WO2004043341A3 (en) Treatment for hemorrhagic shock
HUP0002755A2 (en) Methods for treatment of patients afflicted with multiple sclerosis using consensus interferon
MXPA03008623A (en) Pharmaceutical combinations for the treatment of cancer.
EP1085862A4 (en) Method of treating an autoimmune disorder
WO2002000210A3 (en) Use of agents capable of reducing uric acid levels for the treatment of cardiovascular disease
HK1047707A1 (en) Use of (+)-tramadol, o-demethyltramadol or (+)-o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol or (+)-o-desmethyl-n-mono-desmethyl-tramadol for treating urinary incontinence
CA2268305A1 (en) Use of an h+, k+-atpase inhibitor in the treatment of nasal polyps
GB0020504D0 (en) Therapeutic method
WO2001032071A3 (en) Method of randomizing patients in a clinical trial
WO2003049667A3 (en) The method of treating cancer
EP0744176A3 (en) Methods for inhibiting bone loss
SE9902597D0 (en) New use
WO2000023058A3 (en) Use of an antianaerobic-bacterial or/and antiprotozoal agent (preferably metronidazole) in the manufacture of a medicament for the treatment of haemorrhoids
AU3308099A (en) Method for the treatment of pain, including chronic and female specific pain
AU4259299A (en) New sequences of tt viruses for use in diagnosis, prevention and treatment of ttv infections
WO1996036324A3 (en) Use of a pharmaceutically acceptable oxalate derivative in the manufacture of a medicament for the treatment of skin conditions
MXPA02003329A (en) NOVEL COMBINATION OF LOTEPREDNOL AND beta2.
WO1999064065A3 (en) Tumour therapy and imaging
WO2003045322A3 (en) Method for treating and preventing pancreatitis
AU5434899A (en) Cancer treatment
IL162391A0 (en) Method of treatment

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

122 Ep: pct application non-entry in european phase